Vanda Pharmaceuticals | VNDA - Acreedores Comerciales

Precio De Mercado
7.22
Cambio Diario
-0.11 -1.50%
Mensual
-22.28%
Anual
74.82%
Q2 Expectativa
7.02




Acreedores Comerciales Cambio Fecha
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 18.36M 1.2M 2025-12
Akebia Therapeutics USD 21.18M 11.1M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Anika Therapeutics USD 6.04M 1.31M 2025-12
Arrowhead Research USD 32.94M 15.26M 2025-12
AstraZeneca USD 25.28B 252M 2025-12
Bristol-Myers Squibb USD 4.29B 1.14B 2025-09
Eli Lilly USD 5.38B 1.12B 2025-12
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Heron Therapeutics USD 8.99M 3.02M 2025-12
Insmed USD 79.91M 316K 2025-12
J&J USD 11.99B 2.37B 2025-12
Lexicon Pharmaceuticals USD 3.08M 714K 2025-12
Ligand Pharmaceuticals USD 3.24M 24.52M 2025-12
Merck USD 4.15B 102M 2025-09
Minerva Neurosciences USD 640K 305K 2025-12
Moderna USD 317M 50M 2025-12
Novartis USD 4.46B 99M 2025-12
Pfizer USD 5.02B 142M 2025-09
PTC Therapeutics USD 45.49M 8.87M 2025-12
Puma Biotechnology USD 6.39M 962K 2025-09
Sangamo BioSciences USD 10.74M 7.46M 2025-06
Sanofi EUR 22.93B 927M 2025-12
Takeda JPY 467.59B 28.61B 2025-12
Teva Pharmaceutical Industries USD 2.53B 176M 2025-12
Ultragenyx Pharmaceutical USD 40.57M 6.33M 2025-09
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Veracyte USD 4.59M 916K 2025-12